Table 7.
Antiviral treatment of HCV+ patients by DOPPS country and phase (1996–2015)
| Region/Country | DOPPS Phasea | ||||
|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | |
| Australia/New Zealand | — | 0 (27) | 0 (17) | 0 (26) | 1 (16) |
| Belgium | — | 0 (43) | 0 (27) | 1 (31) | 1 (26) |
| Canada | — | 0 (26) | 1 (29) | 0 (24) | 2 (31) |
| China | — | — | — | 1 (102) | 1 (58) |
| France | 4 (112) | 0 (84) | 3 (66) | 1 (44) | 1 (6) |
| Gulf Cooperation Council | — | — | — | — | 4 (113) |
| Germany | 0 (32) | 1 (26) | 3 (25) | 3 (21) | 1 (41) |
| Italy | 1 (154) | 1 (139) | 2 (99) | 0 (76) | 2 (60) |
| Japan | 0 (498) | 0 (288) | 0 (276) | 1 (188) | 2 (208) |
| Russia | — | — | — | — | 0 (46) |
| Spain | 0 (152) | 2 (92) | 4 (74) | 3 (82) | 2 (84) |
| Sweden | — | 1 (33) | 1 (32) | 1 (35) | 2 (41) |
| Turkey | — | — | — | — | 0 (11) |
| United Kingdom | 0 (15) | 1 (13) | 0 (6) | 1 (17) | 0 (20) |
| United States | 16 (618) | 0 (218) | 2 (136) | 4 (297) | 2 (252) |
| All DOPPS countries | 21 (1581) | 6 (989) | 16 (787) | 16 (943) | 21 (1013) |
Expressed as n treated at enrollment or during follow-up (N HCV+ patients at enrollment); antiviral treatment defined as IFN, ribavirin, or new oral direct Hepatitis C virus inhibitor prescription; medications collected every 4 months in DOPPS phases 1, 3–5, and once yearly in DOPPS phase 2. HCV+, hepatitis C virus-positive; DOPPS, Dialysis Outcomes and Practice Patterns Study; —, not yet joined DOPPS.
a
DOPPS phase 1 (1996–2001 in the United States, 1998–2001 in Europe/Japan); phase 2 (2002–2004); phase 3 (2005–2008); phase 4 (2009–2011); phase 5 (2012–2015).